Treatment with renin-angiotensin system inhibitors (RASIs), such as angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), is the standard therapeutic strategy for patients with CKD [4]. This evidence concerns the gene ACE and chronic kidney disease.